BIO-B — BIO-RAD LABORATORIES, INC.
—
NYSE ·
Unknown ·
Unknown ·
CIK 12208 ·
Last close
$365.08
Market Cap
$1.85B
52W High
$365.08
52W Low
$267.43
ADV30
10
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 651,000,000 | 345,800,000 | 72,600,000 | 371,400,000 | 10,252,000,000 | 517,000,000 | 3,078,100,000 |
| Mar 2026 | 592,100,000 | 309,400,000 | 34,100,000 | -527,100,000 | 9,790,000,000 | 507,200,000 | 2,938,700,000 |
| Dec 2025 | 693,200,000 | 345,200,000 | 53,900,000 | 720,000,000 | 10,576,500,000 | 529,800,000 | 3,122,900,000 |
| Sep 2025 | 653,000,000 | 343,400,000 | 63,900,000 | -341,900,000 | 9,696,400,000 | 395,800,000 | 2,959,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$492,600,000
Investing CF
$-237,100,000
Financing CF
$-120,800,000
CapEx
$-139,500,000
Dividends Paid
—
Buybacks
$-132,700,000
EPS Diluted TTM
$32.62
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$8,020,600,000
Inventory
$780,600,000
Receivables
$441,800,000
ST Investments
$1,101,500,000
EBIT TTM
$399,200,000
Pretax Income TTM
$350,400,000
Interest Exp TTM
$48,800,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,589,299,968
EBITDA
$441,000,000
Free Cash Flow
$283,187,488
Enterprise Value
$9,513,473,024
Total Cash
$1,618,499,968
Total Debt
$1,370,400,000
Shares Out
5,061,038
Trailing EPS
$8.21
Book Value
$268.30
ROE
3.1%
ROA
1.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,583,200,000 | 218,600,000 | 759,900,000 | 10,576,500,000 | 3,122,900,000 | — | 532,200,000 |
| Dec 2024 | 2,566,500,000 | 269,000,000 | -1,844,200,000 | 9,364,100,000 | 2,794,800,000 | — | 455,200,000 |
| Dec 2023 | 2,671,200,000 | 337,800,000 | -637,300,000 | 12,299,100,000 | 3,557,900,000 | — | 374,900,000 |
| Dec 2022 | 2,802,200,000 | 475,100,000 | -3,627,500,000 | 13,501,666,000 | 3,886,414,000 | — | 194,400,000 |
TTM Snapshot
Revenues TTM
$2,563,648,000
NetIncome TTM
$1,518,914,000
OpCashFlow TTM
$0
Assets (Latest)
$9,364,100,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| USA | LIBERTY ALL STAR EQUITY FUND | $1.85B | $6.00 | — |
| ETG | Eaton Vance Tax-Advantaged Global Dividend Income Fund | $1.83B | $24.03 | — |
| NAC | Nuveen California Quality Municipal Income Fund | $1.83B | $11.71 | — |
| STRA | Strategic Education, Inc. | $1.87B | $84.00 | — |
| NUV | NUVEEN MUNICIPAL VALUE FUND INC | $1.88B | $8.95 | — |
News headlines (Yahoo Finance, 1h cache)
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
2026-08-21 14:31 · Yahoo
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
2026-08-14 00:13 · Yahoo
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
2026-08-10 20:05 · Yahoo
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
2026-08-10 13:15 · Yahoo
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus
2026-08-09 22:16 · Yahoo
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary
2026-08-05 12:30 · Yahoo
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ...
2026-08-05 05:02 · Yahoo
Bio-Rad Laboratories Q2 Earnings Call Highlights
2026-08-05 04:03 · Yahoo
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-23 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.